Front Line Genomics’ Post

🚀 Cyclodextrins: New Horizons in Gene Delivery 🧬 In gene therapy, safety and efficiency are paramount. Cyclodextrins, cyclic oligosaccharides derived from starch, are emerging as promising non-viral nanocarriers for genetic material. 🔬 Key Benefits: Biocompatibility: Low toxicity, minimal adverse reactions. Versatility: Efficiently carries DNA, RNA, and siRNA. Controlled Release: Ensures targeted, prolonged therapeutic effects. 🚧 Challenges: Improving transfection efficiency and in vivo performance remains a focus. 🔍 GENEGUT Project: Our Horizon 2020 grant project aims to develop tools for delivering oligonucleotides to treat Crohn's disease. Cyclodextrins offer a safer, versatile alternative to viral vectors, potentially revolutionizing gene therapy. #GeneTherapy #Cyclodextrins #Biotech #Healthcare #GENEGUT

◽️𝐇𝐮𝐦𝐚𝐧 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐓𝐫𝐢𝐚𝐥𝐬: 🔹Human gene therapy trials involve experimental treatments where defective genes in a person's cells are corrected or replaced. 🔹These trials aim to treat genetic disorders by introducing healthy genes into the patient's cells, either in vivo (directly into the body) or ex vivo (cells modified outside the body and then reintroduced). 🔹The process includes preclinical research, clinical trials with phases to test safety and efficacy, and stringent regulatory oversight to ensure patient safety. 🔹Successful trials can lead to groundbreaking treatments for conditions previously deemed untreatable. Image source: Biotechnology by U.Satyanarayana #biotechnology #biotechnologystudent #biotech #science #research #genetics #sciencecommunity #lifescience #carrerinbiotech #futureofbiotech #genetherapy #dikshitaramse

Profluent is making waves in biopharma with its innovative OpenCRISPR initiative. Leveraging large language models, the startup aims to advance CRISPR gene editing by designing unique proteins entirely through AI. Their approach, grounded in massive protein sequence databases, could vastly expand the possibilities for gene therapy development. In a bold move, Profluent has also made its research available through an open-source license, promoting collaboration and acceleration in the field. Discover how AI is driving the next generation of biopharmaceuticals. #biotech #artificialintelligence

#geneediting Exciting News for the Biotech Community! 🧬 Cyagen Offers Cutting-Edge Custom Gene Editing Services! Are you in need of precise and reliable gene editing services for your research or biotech development? Look no further! Cyagen provides a comprehensive range of custom gene editing services, including gene knockouts, knock-ins, point mutations, overexpression, and shRNA interference. Whether for basic gene function studies, drug screening, or gene therapy, Cyagen has got you covered. ✨ What's more, for a limited time, Cyagen is offering a special discount on its gene editing services if you order by December 31st, 2024. ⏰ Take advantage of this promotion to advance your research and development projects! Key Features: ✅ Flexible project types and deliverables tailored to your specific needs ✅ Fast turnaround times, with some services available in as little as 6 weeks ✅ Professional project management and Ph.D.-provided technical support available 24/7 ✅ Strict quality control to ensure the highest standards in deliverables Explore the full range of services and popular cell lines available for gene editing: https://lnkd.in/g_KPEmi5 Don't miss out on this exceptional opportunity to elevate your research and development endeavors. Contact us today and unlock the potential of custom gene editing in advancing your scientific pursuits! #genetherapy #Biotech #ResearchAndDevelopment #Cyagen #CustomGeneEditingServices #ScienceAndInnovation #biosciences #biotechnology #biology #scienceandtechnology

#AAVdownstream challenges: expert insights #AAVvectors are a primary delivery mechanism for #genetherapies due to low immunogenicity, long lasting gene expression, and the ability to target specific tissues. The field of #AAV manufacturing is rapidly expanding, but there are challenges in the downstream processing of these #viralvectors. Next month, an expert panel including Nathalie Clément (VP, Vector Development for Translational Gene Therapies, Siren Biotechnology), Matt Roach (Director of AAV Production, BridgeBio), Nicolas Laroudie (Senior Field Application Scientist, Thermo Fisher Scientific), and William Kish (Principal Scientist - Downstream Process Sciences Engineering, Taysha Gene Therapies) will provide an opportunity to learn more about the latest trends and issues in #AAVmanufacturing, and specifically, how to address the most common downstream processing challenges Register for this #webinar below:

🔬 Research Alert! published in #DrugDevIndPharm 2022, VOL. 48, NO. 1, 1–11 🌟 A cationic cyclodextrin derivative-lipid hybrid nanoparticles for gene delivery effectively promotes stability and transfection efficiency 🌟 This research article explores the development of a novel gene delivery system using lipid-polymer hybrid nanoparticles (LHNPs) composed of α-cyclodextrin-conjugated generation-2 polyamidoamine dendrimers (CDG2) and lipids. The study demonstrates that these CDG2-LHNPs exhibit superior stability and transfection efficiency compared to traditional liposomes and polymers. The nanoparticles were stable for up to 15 days at various temperatures and showed high transfection efficiency mediated by multiple endocytosis pathways, particularly caveolae-mediated endocytosis, which helps avoid lysosomal degradation. The hybrid system's enhanced cell uptake and proton buffering capacity contribute to its effectiveness, making it a promising candidate for gene therapy applications. 📖 Read the full article here: https://lnkd.in/gcxwaYrs #GeneTherapy #Nanoparticles #DrugDelivery

Endpoints News feature **MIT gene editing spinout launches with $213M to write the 'final chapter in genomic medicine'** Full article here: https://lnkd.in/eNStCQtw After more than two years in semi-stealth, Tome Biosciences debuted today with $213 million in Series A and B funding from blue-chip investors, including Andreessen Horowitz ARCH Venture Partners GV (Google Ventures) Longwood Fund Polaris Partners and others. The Watertown, MA-based startup already has 140 employees in its labs just outside of Boston. Its first programs are gene therapies that aim to replace broken code in genetic liver diseases or upload new code to make cell therapies for autoimmune conditions. Led by CEO Rahul Kakkar, who most recently sold Pandion Therapeutics to Merck for almost $2B. More details about the innovation and company at https://tome.bio/ Thank you to Ryan Cross tracking top news and trends in #genomicmedicine #cellandgenetherapy #dna #geneediting

#TRANSFECTION in bioreactors presents several challenges like #Cell Viability, #Scale-Up Compatibility, Homogeneity, Optimization of Conditions, Integration with #Bioreactor System and Long-Term Gene Expression #Stability. These challenges must be addressed to ensure successful gene delivery and expression within the controlled environment of a #bioreactor. Addressing these challenges in transfecting cells within bioreactors requires a comprehensive understanding of both transfection techniques and bioreactor operations, meticulous optimization of transfection parameters, and close monitoring of cell viability, gene expression, and product #quality throughout the process. 

Download TATAA Biocenter’s guide to 𝐏𝐂𝐑 𝐢𝐧 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭!   Curious about the role of PCR in cell and gene therapy drug development? Explore our latest guide where TATAA experts delve deep into the roots, technologies, and applications of PCR.   𝐖𝐡𝐚𝐭'𝐬 𝐈𝐧𝐬𝐢𝐝𝐞: • A journey through PCR's history • Insights into qPCR, dPCR, and Two-tailed PCR • Applications in drug development stages • Choosing the right PCR platform • Assay development insights   TATAA Biocenter accelerates cell and gene therapy drug development! Download the guide now to unleash the power of PCR in your research.   Download here: https://lnkd.in/d2iyXqAc   #PCR #DrugDevelopment #CellTherapy #GeneTherapy #Research

Deep Dive: Adeno-Associated Virus (AAV) Delivery Embark on an enlightening exploration of the rapidly advancing frontier of gene therapy, driven by the pioneering strides in Adeno-Associated Virus (AAV) delivery. Our comprehensive article delves into the expansive landscape of curative treatments, the potential of one-time dosing, and the pivotal role of 2021 in shaping VC investments in this burgeoning sector. From insightful analysis to strategic insights, we navigate the complexities of healthcare innovation with precision and expertise. Join us as we illuminate the path forward in gene therapy. Read more: https://buff.ly/44dISMZ